Neoadjuvant Arterial Infusion Chemotherapy Combined With Immunotherapy in Treating Locally Advanced Lower Esophageal /Esophagogastric Junction Cancer

Author:

Yang Qingjie1,Lv Shenghua2,Li Qingtian2,Lan Linhui2,Sun Xiaoyan2,Feng Xinhai2,Han Kaibao2

Affiliation:

1. Xiamen Humanity hospital, Fujian Medical University

2. Xiamen Humanity hospital,Fujian Medical University

Abstract

Abstract Background: To retrospectively analyze the safety and efficacy of neoadjuvant arterial infusion chemotherapy combined with immunotherapy (neo-AICIT) in treating locally advanced lower esophageal cancer/esophagogastric junction cancers. Methods: The data of patients who received neoadjuvant arterial infusion chemotherapy (docetaxel + cisplatin) combined with immunotherapy (tislelizumab) for locally advanced lower esophageal cancer or esophagogastric junction cancers from October 2021 to June 2022 were collected. The indicators of these patients, such as the clinical staging of tumors, complications of the interventional operation, treatment-related adverse events (TRAEs), the effect of neoadjuvant therapy, operative complications, tumor regression grade (TRG), progression free survival (PFS) and follow-up time, were recorded. Results: A total of 7 patients received a complete neoadjuvant regimen, sequential surgery and postoperative maintenance immunotherapy. The median age was 68. All patients suffered from squamous cell carcinoma; 5 of them had lower esophageal cancer and 2 had esophagogastric junction cancer. The clinical staging in all patients was cT3N0-2M0G1-3. Except for low fever in 1 patient, no other complications of interventional operation occurred. The incidence of grade 1 treatment-related adverse events during the adjuvant therapy was 57.1% (4/7). The postoperative pathology showed that 4 (57.1%, 4/7) patients had pathological complete response (pCR) with a TRG of 3; and 3 (42.9%, 3/7) patients had major pathological remission (MPR) with a TRGof 2. The objective response rate (ORR) was 100%. The median follow-up time was 19 months. Mediastinal group 4 lymph node metastasis was found in 1 patient 18 months after the operation. Tumor recurrence or metastasis was not found in other patients. Conclusion: neo-AICIT has good safety and efficacy in treating locally advanced lower esophageal cancer/esophagogastric junction cancers and may be a promising neoadjuvant therapy.

Publisher

Research Square Platform LLC

Reference26 articles.

1. Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360 – 73. doi:10.1053/j.gastro.2017.08.023. PubMed. PMID: 28823862.

2. Chinese expert consensus on early diagnosis and treatment of esophageal cancer;Early Diagnosis and Treatment Group of Oncology Society, Chinese Medical Association;Chin J Cancer,2022

3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology EaEJC, Version 2.2023. http://www.nccn.org/.

4. Chinese Society of Clinical Oncology Guidelines Working Committee Ecdatg, Version 2023. http://www.csco.org.cn/.

5. Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (cross): Long-term results of a randomised controlled trial. The Lancet Oncology. 2015;16(9):1090-8. doi:10.1016/s1470-2045(15)00040-6. PubMed. PMID: 26254683.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3